Melatonin attenuates colistin-induced nephrotoxicity in rats

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4044-4049

  Yousef, Jumana M ^a   Chen, Gong ^a   Hill, Prue A ^b   Nation, Roger L ^a   Li, Jian ^a  

^a MONASH UNIVERSITY   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; CREATININE; MELATONIN; N ACETYL BETA GLUCOSAMINIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG CLEARANCE; ENZYME RELEASE; HISTOLOGY; MALE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RENAL PROTECTION; TREATMENT DURATION; URINARY EXCRETION;

ACETYLGLUCOSAMINIDASE; ANIMALS; COLISTIN; CREATININE; KIDNEY; MALE; MELATONIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 80051805882     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00328-11     Document Type: Article

References (48)

1. Antoniadou, A., et al. 2007. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: First report of a multiclonal cluster. J. Antimicrob. Chemother. 59:786-790. (Pubitemid 47073420)
2. Beno, P., V. Krcmery, and A. Demitrovicova. 2006. Bacteremia in cancer patients caused by colistin-resistant Gram-negative bacilli after previous exposure to ciprofloxacin and/or colistin. Clin. Microbiol. Infect. 12:497-498.
3. Bergen, P J, et al. 2010. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob. Agents Chemother. 54:3783-3789.
4. Bergen, P J, J. Li, C R Rayner, and R L Nation. 2006. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:1953-1958. (Pubitemid 43807511)
5. Celik, I., M. Cihangiroglu, N. Ilhan, N. Akpolat, and H H Akbulut. 2005. Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity. Basic Clin. Pharmacol. Toxicol. 97:325-332. (Pubitemid 41608127)
6. Dudhani, R V, J D Turnidge, R L Nation, and J. Li. 2010. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J. Antimicrob. Chemother. 65:1984-1990.
7. Evans, M E, D J Feola, and R P Rapp. 1999. Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant gram-negative bacteria. Ann. Pharmacother. 33:960-967. (Pubitemid 29420995)
8. Falagas, M E, K N Fragoulis, S K Kasiakou, G J Sermaidis, and A. Michalopoulos. 2005. Nephrotoxicity of intravenous colistin: A prospective evaluation. Int. J. Antimicrob. Agents 26:504-507. (Pubitemid 41635502)
9. Falagas, M E, and S K Kasiakou. 2005. Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40:1333-1341. (Pubitemid 40570245)
10. Falagas, M E, S K Kasiakou, D P Kofteridis, G. Roditakis, and G. Samonis. 2006. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 25:596-599. (Pubitemid 44379694)
11. Falagas, M E, et al. 2005. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect. Dis. 5:1.
12. Garonzik, S M, et al. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55:3284-3294.
13. Garrison, W M 1987. Reaction mechanisms in the radiolysis of peptides, polypeptides, and proteins. Chem. Rev. 87:381-398.
14. Hartzell, J D, et al. 2009. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin. Infect. Dis. 48:1724-1728.
15. Holmes, K K 1964. Toxicity of colistin and polymyxin B. N. Engl. J. Med. 271:633-634.
16. Horak, E., S M Hopfer, and F W Sunderman, Jr. 1981. Spectrophotometric assay for urinary N-acetyl-beta-D-glucosaminidase activity. Clin. Chem. 27:1180-1185. (Pubitemid 11071855)
17. Horton, J, and G A Pankey. 1982. Polymyxin B, colistin, and sodium colistimethate. Med. Clin. N. Am. 66:135-142. (Pubitemid 12154259)
18. Jin, L., J. Li, R L Nation, and J A Nicolazzo. 2009. Brain penetration of colistin in mice assessed by a novel high-performance liquid chromatographic technique. Antimicrob. Agents Chemother. 53:4247-4251.
19. Kallel, H., et al. 2007. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: A matched case-control study. Intensive Care Med. 33:1162-1167. (Pubitemid 47036903)
20. Ko, H., et al. 2011. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin. Pract. 117:c284-c288.
21. Koch-Weser, J., et al. 1970. Adverse effects of sodium colistimethate: Manifestations and specific reaction rates during 317 courses of therapy. Ann. Intern. Med. 72:857-868.
22. Koomanachai, P., S. Tiengrim, P. Kiratisin, and V. Thamlikitkul. 2007. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int. J. Infect. Dis. 11:402-406. (Pubitemid 47239447)
23. Landman, D., C. Georgescu, D A Martin, and J. Quale. 2008. Polymyxins revisited. Clin. Microbiol. Rev. 21:449-465.
24. Li, J., et al. 2001. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J. Chromatogr. B, Biomed. Sci. Appl. 761:167-175. (Pubitemid 32817106)
25. Li, J., R W Milne, R L Nation, J D Turnidge, and K. Coulthard. 2003. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob. Agents Chemother. 47:1364-1370. (Pubitemid 36368598)
26. Li, J., et al. 2003. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob. Agents Chemother. 47:1766-1770. (Pubitemid 36548571)
27. Li, J., et al. 2004. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J. Antimicrob. Chemother. 53:837-840. (Pubitemid 38660288)
28. Li, J., R L Nation, R W Milne, J D Turnidge, and K. Coulthard. 2005. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int. J. Antimicrob. Agents 25:11-25. (Pubitemid 40023341)
29. Li, J., et al. 2006. Colistin: The re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601.
30. Lockwood, T D, and H B Bosmann. 1979. The use of urinary N-acetyl-β-glucosaminidase in human renal toxicology. I. Partial biochemical characterization and excretion in humans and release from the isolated perfused rat kidney. Toxicol. Appl. Pharmacol. 49:323-336. (Pubitemid 9231866)
31. Lopez-Novoa, J M, Y. Quiros, L. Vicente, A I Morales, and F J Lopez-Hernandez. 2011. New insights into the mechanism of aminoglycoside nephrotoxicity: An integrative point of view. Kidney Int. 79:33-45.
32. Ma, Z., et al. 2009. Renal disposition of colistin in the isolated perfused rat kidney. Antimicrob. Agents Chemother. 53:2857-2864.
33. Nation, R L 2010. Towards optimized colistin dosing, p. 32. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
34. Nation, R L, and J. Li. 2009. Colistin in the 21st century. Curr. Opin. Infect. Dis. 22:535-543.
35. Nord, N M, and P D Hoeprich. 1964. Polymyxin B and colistin: A critical comparison. N. Engl. J. Med. 270:1030-1035.
36. Ozbek, E., et al. 2000. Melatonin administration prevents the nephrotoxicity induced by gentamicin. BJU Int. 85:742-746. (Pubitemid 30192846)
37. Ozyilmaz, E., et al. 2010. Could nephrotoxicity due to colistin be ameliorated with the use of N-acetylcysteine? Intensive Care Med. 37:141-146.
38. Parlakpinar, H., et al. 2003. Amikacin-induced acute renal injury in rats: Protective role of melatonin. J. Pineal Res. 35:85-90. (Pubitemid 36960346)
39. Racusen, L, and M. Kashgarian. 2007. Ischemic and toxic tubular injury and other ischemic renal injury, p. 1139-1198. In J. C. Jenette et al. (ed.), Pathology of the kidney. Lippincott/Williams & Walters, New York, NY.
40. Reiter, R J, et al. 1995. A review of the evidence supporting melatonin's role as an antioxidant. J. Pineal Res. 18:1-11.
41. Reiter, R J, D X Tan, R M Sainz, and J C Mayo. 2002. Melatonin: Reducing the toxicity and increasing the efficacy of drugs. J. Pharm. Pharmacol. 54:1299-1321. (Pubitemid 35174175)
42. Seabra, M L, M. Bignotto, L R Pinto, Jr., and S. Tufik. 2000. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J. Pineal Res. 29:193-200.
43. Sener, G., et al. 2000. The protective effect of melatonin on cisplatin nephrotoxicity. Fundam. Clin. Pharmacol. 14:553-560. (Pubitemid 32054382)
44. Sener, G., et al. 2002. Melatonin protects against gentamicin-induced nephrotoxicity in rats. J. Pineal Res. 32:231-236. (Pubitemid 34478284)
45. Stadtman, E R, and R L Levine. 2003. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 25:207-218. (Pubitemid 38043943)
46. Sugden, D. 1983. Psychopharmacological effects of melatonin in mouse and rat. J. Pharmacol. Exp. Ther. 227:587-591. (Pubitemid 14215038)
47. Tomas-Zapico, C, and A. Coto-Montes. 2007. Melatonin as antioxidant under pathological processes. Recent Patents Endocrine Metabol. Immune Drug Disc. 1:63-82.
48. Wallace, S J, et al. 2008. Subacute toxicity of colistin methanesulfonate in rats: Comparison of various intravenous dosage regimens. Antimicrob. Agents Chemother. 52:1159-1161. (Pubitemid 351358406)